Subtype
Brain Neoplasm
CI-CAN-00002030Explore in graph →
Non-malignant511 active trials34 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002030Explore in graph →
Clinical trials
2,117 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05835687 | Loc3CAR: Locoregional Delivery of B7-H3-CAR T Cells for Pediatric Patients With Primary CNS Tumors | active not recruiting | Phase 1 | 29 | St. Jude Children's Research HospitalOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT02390518 | Stereotactic Radiosurgery Dose Escalation for Brain Metastases | recruiting | Phase 1 | 86 | University of UtahOTHER | 1 | Jul 2, 2026 | clinicaltrials |
| NCT07118176 |
| Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers |
| active not recruiting |
| Phase 1 |
| 30 |
| Jonsson Comprehensive Cancer CenterOTHER |
| 1 |
| Jul 2, 2026 |
| clinicaltrials |
| NCT03510208 | Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery | recruiting | Phase 1 / Phase 2 | 46 | Stanford UniversityOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT03299309 | PEP-CMV in Recurrent MEdulloblastoma/Malignant Glioma(PRiME) | active not recruiting | Phase 1 | 30 | Daniel LandiOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06193759 | Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)(IMPACT) | recruiting | Phase 1 | 12 | Children's National Research InstituteOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT06104488 | A Study of Avutometinib for People With Solid Tumor Cancers | active not recruiting | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06666712 | Chronic CED of TPT for Recurrent Malignant Glioma(TPT CED rHGG) | recruiting | Phase 1 | 6 | Jeffrey N. BruceOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06914479 | Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors | recruiting | Phase 1 | 11 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05521984 | Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i) | recruiting | Phase 1 | 20 | Washington University School of MedicineOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT07629089 | VorAsidenib With Lomustine In Patients With rEcurrent IDH-mutaNT Glioma Harboring IDH1 and/or IDH2 Mutations(VALIENT) | not yet recruiting | Phase 1 | 24 | Megan ManticaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT02649582 | Adjuvant Dendritic Cell-immunotherapy Plus Temozolomide in Glioblastoma Patients(ADDIT-GLIO) | active not recruiting | Phase 1 / Phase 2 | 20 | University Hospital, AntwerpOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT06607692 | Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).(LUPARPED) | recruiting | Phase 1 / Phase 2 | 25 | Fundación de investigación HMOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT07223034 | A Study of 177Lu-PSMA-617 in People With Gliomas | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04978727 | A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma | active not recruiting | Phase 1 | 35 | Children's Oncology GroupNETWORK | 2 | Jun 2, 2026 | clinicaltrials |
| NCT02861898 | Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 33 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT03213002 | Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM(CAPTEM) | recruiting | Phase 1 / Phase 2 | 67 | Northwell HealthOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06807619 | A Study of Sotorasib in People With Brain Tumors | recruiting | Phase 1 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT02696993 | Nivolumab and Radiation Therapy With or Without Ipilimumab in Treating Patients With Brain Metastases From Non-small Cell Lung Cancer | active not recruiting | Phase 1 / Phase 2 | 80 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06048094 | 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery(FACILITATE) | recruiting | Phase 1 | 46 | Baptist Health South FloridaOTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT06673329 | Brodalumab in the Treatment of Immune-Related Adverse Events | recruiting | Phase 1 | 11 | Brian Henick, MDOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07003139 | A Study of the Boron Neutron Capture Therapy (BNCT) Using B10 L-BPA in Malignant Brain Tumors | recruiting | Phase 1 / Phase 2 | 10 | China Medical University HospitalOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT07584499 | Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors(MRG003) | recruiting | Phase 1 | 51 | Sun Yat-sen UniversityOTHER | 1 | May 13, 2026 | clinicaltrials |
| NCT05293197 | Safety Study of the Repeated Opening of the Blood-brain Barrier With the SonoCloud® Device to Treat Malignant Brain Tumors in Pediatric Patients(SONOKID) | recruiting | Phase 1 | 24 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT07569042 | A Rollover Study of NBM-BMX in Combination With Temozolomide in Patients With Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 15 | Novelwise Pharmaceutical CorporationINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT03465618 | A First in Human Study Using 89Zr-cRGDY Ultrasmall Silica Particle Tracers for Malignant Brain Tumors | active not recruiting | Phase 1 | 17 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT02993146 | Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients With Brain Metastases | active not recruiting | Phase 1 | 11 | National Cancer Institute (NCI)NIH | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06012695 | NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 79 | Novelwise Pharmaceutical CorporationINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT04689048 | Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery | recruiting | Phase 1 | 20 | Baptist Health South FloridaOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT05615623 | Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric DIPG | active not recruiting | Phase 1 / Phase 2 | 10 | InSightecINDUSTRY | 1 | Apr 21, 2026 | clinicaltrials |
| NCT05630209 | Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) | active not recruiting | Phase 1 / Phase 2 | 10 | InSightecINDUSTRY | 1 | Apr 17, 2026 | clinicaltrials |
| NCT04185038 | Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors | recruiting | Phase 1 | 90 | Seattle Children's HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06810544 | Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | recruiting | Phase 1 / Phase 2 | 191 | Tango Therapeutics, Inc.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03605550 | A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma | active not recruiting | Phase 1 | 64 | Nationwide Children's HospitalOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT02852655 | A Pilot Surgical Trial To Evaluate Early Immunologic Pharmacodynamic Parameters For The PD-1 Checkpoint Inhibitor, Pembrolizumab (MK-3475), In Patients With Surgically Accessible Recurrent/Progressive Glioblastoma | active not recruiting | Phase 1 | 60 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 20, 2026 | clinicaltrials |
| NCT03478462 | Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas(CLOVER-2) | active not recruiting | Phase 1 | 30 | Cellectar Biosciences, Inc.INDUSTRY | 3 | Mar 18, 2026 | clinicaltrials |
| NCT04943848 | rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG | recruiting | Phase 1 | 36 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT07456878 | Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas | recruiting | Phase 1 | 5 | Mayo ClinicOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04510051 | CAR T Cells After Lymphodepletion for the Treatment of IL13Rα2 Positive Recurrent or Refractory Brain Tumors in Children | recruiting | Phase 1 | 18 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT04661384 | Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma | active not recruiting | Phase 1 | 10 | City of Hope Medical CenterOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT03152318 | A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2(rQNestin) | active not recruiting | Phase 1 | 62 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07438860 | Fluorescence-Guided Imaging of Brain Tumors: A Safety Study Using SBK2-ICG | not yet recruiting | Phase 1 | 12 | Tiffany HodgesOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06342908 | A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma | active not recruiting | Phase 1 | 6 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT04478279 | A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 125 | Sapience TherapeuticsINDUSTRY | 2 | Feb 9, 2026 | clinicaltrials |
| NCT04459273 | Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers(FAPI PET RDRC) | active not recruiting | Phase 1 | 26 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT06650163 | Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors | recruiting | Phase 1 | 20 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03324360 | Role of Hyperpolarized 13C-Pyruvate MR Spectroscopy in Patients With Intracranial Metastasis Treated With (SRS) | recruiting | Phase 1 | 276 | Sunnybrook Health Sciences CentreOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05762419 | FUS Etoposide for DMG | recruiting | Phase 1 | 10 | Columbia UniversityOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT06208657 | Optimal Precision TherapIes to CustoMISE Care in Childhood and Adolescent Cancer | recruiting | Phase 1 / Phase 2 | 90 | Australian & New Zealand Children's Haematology/Oncology GroupOTHER | 2 | Jan 28, 2026 | clinicaltrials |
| NCT06815432 | GPC-3 CAR T CELLS FOR Recurrent GPC-3 Positive Glioblastoma | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Jan 28, 2026 | clinicaltrials |
Data updated 22 days agoSource updated Jul 6, 2026source: clinicaltrials